This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that a poster entitled “LGD-6972, a Potent, Orally-Bioavailable, Small Molecule Glucagon Receptor Antagonist for the Treatment of Type 2 Diabetes” was presented at the 72nd Scientific Sessions of the American Diabetes Association (ADA), June 8-12, 2012, in Philadelphia. The poster provides data from preclinical studies of a novel compound, LGD-6972 that has demonstrated promising glucose lowering activity in various animal models of type 2 diabetes.
In preclinical studies, Ligand evaluated the efficacy, pharmacokinetics, and safety of LGD-6972.
The key findings include:
LGD-6972 is a highly potent and selective glucagon receptor antagonist
LGD-6972 inhibits glucagon-induced hyperglycemia in both rats and monkeys
LGD-6972 lowers glucose in a mouse model of type 2 diabetes mellitus
Preclinical studies demonstrated robust pharmacokinetics and predict LGD-6972 will be amenable to once daily oral dosing in humans
IND-enabling safety studies support the initiation of clinical development planning for LGD-6972
“We are extremely pleased with our R&D team’s progress on LGD-6972. Type 2 diabetes is the most common form of diabetes and is a major and quickly growing global health concern that currently affects over 200 million people worldwide,” said Matthew W. Foehr, Chief Operating Officer of Ligand Pharmaceuticals. “LGD-6972 is an extremely promising and differentiated novel agent with significant market potential and a strong intellectual property position. Glucagon receptor antagonists represent a clinically validated new class of molecules for the treatment for Type 2 diabetes. We see LGD-6972 as one of our most promising unpartnered preclinical assets.”
About Ligand’s Glucagon Receptor Antagonist Program
Glucagon is a hormone produced by the pancreas that stimulates the liver to produce glucose (sugar). Overproduction of glucose by the liver is an important cause of high glucose levels in patients with type 2 diabetes and is believed to be due in part to inappropriately elevated levels of glucagon. High glucose levels can cause diabetic complications such as blindness and kidney disease. Glucagon receptor antagonists are designed to lower glucose levels by reducing the production of glucose by the liver. Glucagon receptor antagonists are novel molecules that have demonstrated a reduction of glucose and hemoglobin A1c in mid-stage clinical trials.